La Jolla Pharmaceutical — Investor Presentation (May 2013)
40 slides from La Jolla Pharmaceutical's investor presentation, May 16, 2013
Slide 1: Pioneering Innovative Therapies to Treat Chronic Organ Failure
Pioneering Innovative Therapies to Treat Chronic Organ Failure George F. Tidmarsh, MD, PhD Chief Executive Officer May 2013 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp
Slide 3: An Introduction to La Jolla (LJPC)
An Introduction to La Jolla (LJPC) The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 4: Mission
Mission La Jolla Pharmaceutical: Reducing Human Suffering Novel Therapies Harnessing the Immune System To Treat Life-Threatening Diseases
Slide 5: Corporate Highlights
Corporate Highlights Corporate Highlights Technology Background Pipeline Experienced Management • George F. Tidmarsh, MD, PhD, Chief Executive Officer Milestones • Near-term, cost-efficient Phase 2 clinical milestones to drive value Stanford University MD/PhD, Associate Professor, Pediatrics and Neo
Slide 6: Robust Product Pipeline
Robust Product Pipeline Robust Product Pipeline
Slide 7: An Introduction to La Jolla
An Introduction to La Jolla The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 8: Galectins and Galectin-3
Galectins and Galectin- 3 3 Galectins and Galectin-3 • Galectins are proteins that can bind to specific sugars on other proteins (receptors) to modulate cellular function and communication. • Galectin-3 is unique in that it can self-associate allowing it to bind to several receptors at once. • Galec
Slide 9: GCS-100: The Leading Galectin-3 Antagonist
GCS-100: The Leading Galectin-3 Antagonist GCS-100: The Leading Galectin-3 Antagonist • GCS-100 is a well-characterized, complex sugar derived from pectin • GCS-100 binds to and neutralizes galectin-3. Binding activity is localized to the galactose containing side-branches • Patented manufacturing p
Slide 10: An Introduction to La Jolla
An Introduction to La Jolla The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 11: Galectin-3 and Organ Failure Kidney, Heart, Liver
Galectin-3 and Organ Failure Kidney, Heart, Liver Galectin-3 and Organ Failure Kidney, Heart, Liver • Mice lacking galectin-3 develop significantly less kidney fibrosis and failure after damage compared to normal mice 1,2 • Mice lacking galectin-3 develop significantly less liver fibrosis when expos
Slide 12: Galectin-3 in the General Population
Galectin-3 in the General Population Galectin-3 in the General Population
Slide 13: Galectin-3 in the General Population
Galectin-3 in the General Population Galectin-3 in the General Population • High galectin-3 is independently associated with lower survival in the general population Journal of Internal Medicine, 2012, 272; 55-64.
Slide 14: Galectin-3: Promotes Organ Failure via Scar Formation
Galectin-3: Promotes Organ Failure via Scar Formation Galectin-3: Promotes Organ Failure via Scar Formation • Mice genetically altered to lack galectin-3 produce much less scar tissue in the kidney after injury. Normal (wild-type, WT) mice or galectin-3 knockout mice were either left alone (-) or su
Slide 15: Chronic Kidney Disease Market
Chronic Kidney Disease Market Chronic Kidney Disease Market • 49 million Americans suffer with CKD • $7.1 billion spent on CKD therapeutics in • Market growth of 6.4% CAGR over the next 5 years The United States Renal Data System, 2012 Annual Data Report $7.1 $11.7 $7.0 $8.0 $9.0 $10.0 $11.0 $12.0 C
Slide 16: Liver Disease Market
Liver Disease Market Liver Disease Market The National Institute of Diabetes and Digestive and Kidney Diseases Liver Disease Treatments: The Global Market, January 1, BCC Research • 17.5 million Americans suffer with CLD • $12.4 billion spent on CLD therapeutics in • CLD market growth of 3.3% CAGR e
Slide 17: GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model
GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model Boehringer Ingelhiem GmbH & Co. KG Galectin Therapeutics Effect of GCS-100 in liver fibrosis was studied by an independent, contract research group The 61 st annual meeting of the Amer
Slide 18: Stelic NASH Model
Stelic NASH Model Stelic NASH Model Treatment Control GCS-100 1 mg/kg GCS-100 25 mg/kg Endpoints Pathology Serum Chemistry NAFLD Score Fibrosis
Slide 19: GCS-100 Treatment Reduced Liver Fibrosis
GCS-100 Treatment Reduced Liver Fibrosis GCS-100 Treatment Reduced Liver Fibrosis Each circle represents data from one mouse.
Slide 20: GCS-100 Treatment Reduced Liver Fibrosis
GCS-100 Treatment Reduced Liver Fibrosis GCS-100 Treatment Reduced Liver Fibrosis
Slide 21: GCS-100 Improved Gross Pathology
GCS-100 Improved Gross Pathology GCS-100 Improved Gross Pathology Vehicle GCS-100
Slide 22: GCS-100 Effect of NASH: Summary
GCS-100 Effect of NASH: Summary GCS-100 Effect of NASH: Summary • Significant reduction in fibrosis as measured by Sirius Red staining • Significant reduction in NAFLD score • Significant reduction in plasma ALT • No change in: Body weight Serum glucose Liver weight Liver hydroxyproline Collagen mRN
Slide 23: An Introduction to La Jolla
An Introduction to La Jolla The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 24: GCS-100 Clinical Summary
GCS-100 Clinical Summary GCS-100 Clinical Summary • 179 patients dosed in 10 Phase 1 and Phase 2 clinical trials • Pharmacokinetic parameters established Single- and multiple-dose administration of 30-160 mg/m Effective half-life in blood of 36 hours • Evidence of positive effect on renal function
Slide 25: Source of Patients in Retrospective Analysis
Source of Patients in Retrospective Analysis Study No. Design Treated Population Treatments # Patients with eGFR <60 Source of Patients in Retrospective Analysis PR-CS008 Phase 2 24 CLL 160 mg/m days 1-5 GLY-101-01 Phase 1 24 subjects various solid tumors 30-200 mg/m days 1-5 GCS-100-01-001 Phase 1
Slide 26: Low Dose GCS-100 Increases Renal Function
Low Dose GCS-100 Increases Renal Function Low Dose GCS-100 Increases Renal Function 17 patients treated with low dose GCS-100 GCS-100
Slide 27: GCS-100 Clinical Summary
GCS-100 Clinical Summary GCS-100 Clinical Summary • Well tolerated and tolerable side effects based on 179 patients treated to date Principle side effects: mild rash, joint pain, muscle pain • Dosing exposure up to 1000 mg/m per week • Evidence for improving kidney function
Slide 28: An Introduction to La Jolla
An Introduction to La Jolla The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 29: Clinical Trial Rationale
Clinical Trial Rational Clinical Trial Rational • Galectin-3 is increased and the level correlates to overall survival in end-stage renal disease patients • Galectin-3 knockout mice develop less kidney scar after injury • Retrospective analysis shows low dose GCS-100 improves renal function in patie
Slide 30: CKD Phase 1/2 Trial Phase 1 Portion Complete
CKD Phase 1/2 Trial Phase 1 Portion Complete CKD Phase 1/2 Trial Phase 1 Portion Complete Part A Day -21 Day -8 Day Day Screening Visit 1 Screening Visit 2 Each cohort n=3 patients (up to 6 cohorts) GCS-100 1.5-20 mg/m ² IV D – -21,-8 Data collected on: Blood gal-3, Cytokine, Serum chemistry, Quanti
Slide 31: Proposed Phase 2a CKD Trial
Proposed Phase 2a CKD Trial Proposed Phase 2a CKD Trial Day Day Day Day D – 0,7 GCS-100 PBO, 1.5 & 20 mg/m ² IV Data collected on: Blood gal-3, Cytokine, Serum chemistry, Quantitative urine analysis, and eGFR rate Data Collection Point Dosing Point Key Day Day Day Day D – 14,21 D – 28,35 D – 42,49 D
Slide 32: GCS-100 in CKD Status
GCS-100 in CKD Status GCS-100 in CKD Status • Phase 1 Complete 4 leading sites in the US Enrolled 29 patients in 3 months • Accelerated path to Phase 2 Data Randomized, 3 arm study proposed – Endpoints: - Change in renal function compared to placebo Protocol currently under review at FDA
Slide 33: An Introduction to La Jolla
An Introduction to La Jolla The Technology of La Jolla GCS-100 and Organ Failure GCS-100’s History in the Clinic Phase 1/2 Clinical Trial Patents and Financials
Slide 34: Intellectual Property Position
Title Status Expiration Intellectual Property Position Modified Pectins, Compositions and Methods Related Thereto Issued US 8,128,966 Modified Pectins, Compositions and Methods Related Thereto Issued US 8,187,642 Modified Pectins, Compositions and Methods Related Thereto Pending US 13/588,932 Modifi
Slide 35: Assets
Assets Assets March 31, 2013 December 31, 2012 Assets Cash and Cash equivalents 2,700 3,405 Restricted cash – Prepaids and other current assets Total current assets 2,813 3,430 Total Assets 2,813 3,430
Slide 36: Liabilities, Shareholders' Equity
Liabilities, Shareholders’ Equity Liabilities, Shareholders’ Equity March 31, December 31, Current Liabilities: Accounts payable Accrued expenses Accrued payroll and related expenses Total current liabilities Stockholders’ equity: Common stock Preferred stock 10,888 10,907 Additional paid-in capital
Slide 37: Stock Information
Stock Information Stock Information Stock Price $0.08 Shares Outstanding 30,486,228 Market Cap $2,438,898 Price Range (52 Week) $0.04 – $0.14 Avg. Volume 215,857 33.3% Gain in stock price since 12/31/12 & up 100% gain on intra day trading $0.050 $0.070 $0.090 54.0% Outstanding Common Stock Public Fl
Slide 38: Robust Product Pipeline
Robust Product Pipeline Robust Product Pipeline
Slide 39: Corporate Highlights
Corporate Highlights Corporate Highlights Technology Background Pipeline May prevent or reverse organ failure by reducing fibrosis via neutralization of galectin-3 Phase 1 and 2 clinical safety data with evidence for activity improving kidney function Management Experienced and driven Milestones Nea
Slide 40: @LaJolla
/ @Lavolla
LA Jolla Pharmaceutical — Investor Presentation (May 2013) on 6ix